Locations:
Search IconSearch
December 9, 2025/Cancer/News & Insight

Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

church bus tour

Black Americans have a significantly higher incidence, severity and mortality from venous thromboembolism (VTE) compared to other racial and ethnic groups. Despite this elevated risk, awareness and education about VTE remain limited in many Black communities.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To address this knowledge gap, the National Blood Clot Alliance launched the Black Lives Advocating for Clot Knowledge (B.L.A.C.K) Church Bus Tour, which partnered with faith-based institutions in southeastern Black communities. This program aimed to empower individuals to recognize VTE risk factors and symptoms, know when to seek prompt care and learn about preventive actions.

A bold approach

Featuring a bright-red bus with signage describing VTE symptoms, the campaign educated individuals to take steps to reduce the risk of VTE and to recognize the condition when it occurs. The bus tour included four churches in Charlotte, NC, Marietta, GA and Memphis, TN. The tour incorporated educational sessions and the distribution of educational materials.

Researchers collected pre- and post-event surveys to assess changes in knowledge resulting from the program. The findings were presented at the 2025 ASH annual meeting.

“The NBCA bus tour campaign underscores the value of culturally tailored educational interventions in addressing gaps in VTE awareness,” says Dana Angelini, MD, a physician in the Classical Hematology team at Cleveland Clinic Cancer Institute.

Program demographics

More than 450 people participated in the events across the southeastern U.S. The majority of participants were between 61-70 years old, and 73.1% were female. Most participants identified as Black, non-Hispanic.

Roughly 89% participants said they had not personally experienced a blood clot and they did not have a friend or family member who had experienced one.

Advertisement

Increasing awareness

Wilcoxon signed-rank test was used to compare section and total survey scores before and after the program. Analysis of the pre- and post-surveys found a statistically significant increase in awareness across 16 knowledge domains. In addition to gaining knowledge about symptoms and treatments, the overwhelming majority of participants also strongly agreed to make lifestyle changes to reduce their risk of contracting VTE.

Additionally, most participants reported their intention to share this knowledge in the community. “This finding demonstrates the power that community education has to spread awareness to those who are in front of us and beyond,” says Dr. Angelini.

What’s next

Based on the success of the program, the National Blood Clot Alliance is working on a “2.0” version of the bus tour, and hopes to make this an annual endeavor. The plan is to continue to raise awareness in the hopes of fostering earlier intervention and risk mitigation and ultimately reduce VTE-associated mortality rates. “This initiative highlights the importance of meeting people where they are, in environments where they feel comfortable, and providing them with trusted health education.,” says Dr. Angelini.

Advertisement

Related Articles

Medical illustration of blood cells
August 25, 2026/Cancer/Benign Hematology

Understanding Rebalancing Agents

Newer class of medications evolves care models for patients with hemophilia

Patient greeting physician
August 12, 2026/Cancer/Benign Hematology

Classical Hematology 2.0

Improving access to specialists

Large meningiolma
August 6, 2026/Cancer/Brain Tumor

Case Study: Patient with Large Meningioma Thriving After Treatment

Dotatate PET/CT scan and molecular testing informed treatment trajectory

Young couple cooking
July 27, 2026/Cancer/Patient Support

Empowering Cancer Survivors through Lifestyle Medicine

A proactive, framework-based approach

Physician checking patient's heart rate
July 15, 2026/Cancer

First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events

Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.

Thyroid cancer illustration
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Ad